Corporate Events

KYORIN Pharmaceutical Co., Ltd., Board Meeting, May 21, 2025. Agenda: to distribute retained earnings with the record date of March 31, 2025.

KYORIN Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Jul 31, 2025

KYORIN Pharmaceutical Co., Ltd., ¥ 5.00, Cash Dividend, Mar-28-2025

KYORIN Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2025.

KYORIN Pharmaceutical Co., Ltd. provided year end dividend guidance for the year ending March 31, 2026. The company expects to pay year end dividend of JPY 37.00 per share for the year ending March 31, 2026 compared to JPY 32.00 per share paid a year ago.

KYORIN Pharmaceutical Co., Ltd. announced special dividend of JPY 5.00 per share for the year ended March 31, 2025. Scheduled date for starting dividend payment: June 5, 2025.

KYORIN Pharmaceutical Co., Ltd. announced year end dividend of JPY 32.00 per share for the year ended March 31, 2025 compared to JPY 32.00 per share paid a year ago. Scheduled date for starting dividend payment: June 5, 2025. The company expects to pay dividend of JPY 20.00 per share for the second quarter of fiscal year ending March 31, 2026.

KYORIN Pharmaceutical Co., Ltd. provided consolidated and non-consolidated earnings guidance for the first half and full year of fiscal year ending March 31, 2026. For the first half, on consolidated basis, the company expects net sales of JPY 57,400 million, operating profit of JPY 1,700 million and profit attributable to owners of parent of JPY 1,400 million or JPY 24.37 per share. For the year ending March 31, 2026, on consolidated basis, the company expects net sales of JPY 127,000 million, operating profit of JPY 6,100 million and profit attributable to owners of parent of JPY 4,800 million or JPY 83.55 per share. For the first half, on non-consolidated basis, the company expects net sales of JPY 50,300 million, operating profit of JPY 2,100 million and profit of JPY 1,800 million or JPY 31.33 per share. For the year ending March 31, 2026, on consolidated basis, on non-consolidated basis, the company expects net sales of JPY 111,100 million, operating profit of JPY 6,300 million and profit of JPY 5,100 million or JPY 88.76 per share.

KYORIN Pharmaceutical Co., Ltd., Board Meeting, May 12, 2025. Agenda: To consider the Notice Regarding Revision to Annual Dividend Forecast (Special Dividend).

KYORIN Pharmaceutical Co., Ltd. announced that it entered into a global license agreement with Novartis Pharma AG on March 3, 2025, for KRP-M223 and its back-up compounds discovered by KYORIN. Under this agreement, KYORIN grants Novartis an exclusive worldwide license to develop, manufacture, and commercialize KRP-M223. KYORIN retains an option to commercialize in Japan and manufacture the product for the Japan market with Novartis retaining an option to co-promote with KYORIN in Japan. KYORIN will receive an upfront payment of USD 55 million and is eligible to receive milestone payments of up to USD 777.5 million tied to the progress of development, approval, and commercialization of KRP-M223 as well as tiered royalties on net sales. KRP-M223 is an MRGPRX2 antagonist for allergic and inflammatory diseases involving mast cells, such as chronic spontaneous urticaria. KYORIN has developed KRP-M223 which now is in the pre-clinical stage and Novartis will be responsible for global development. KYORIN aims to create high-value new drugs that meet medical needs under its long-term vision "Vision 110". KYORIN aims to contribute to better health through the global development of its products. The impact of this transaction on consolidated financial forecast for the fiscal year ending March 2025 is currently under review.

KYORIN Pharmaceutical Co., Ltd. announced that KYORIN has entered into a development and commercialization agreement with Hyfe Inc. (Wilmington DE, CEO: Tamsin Chislett) for digital therapeutics (DTx) for chronic cough and are currently developing the DTx in Japan. The DTx for chronic cough under development is based on the principles of BCST (Behavioral Cough Suppression Therapy), which is a non-pharmacological treatment method used to reduce chronic cough by facilitating changes in patient behavior, and utilizes cough monitoring technology powered by Hyfe's AI. KYORIN will develop DTx tailored for the Japanese market using expertise in respiratory diseases. Based on this agreement, KYORIN will pay Hyfe milestone payments tied to the progress of developing and commercializing the DTx product, and royalties based on net sales following its launch. KYORIN aims to create high-value new drugs that meet medical needs under its long-term vision "Vision 110", and contribute to clinical development by providing new treatment options for chronic cough. The impact on business performance for the fiscal year ending March 2025 is to be negligible.

Cyrano Therapeutics, Inc. announced that on February 14, 2025 it entered into an option agreement with KYORIN Pharmaceutical Co. Ltd. for CYR-064, a novel treatment for post-viral loss of smell (hyposmia). Under this agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064 in Japan and will pay an option fee to Cyrano. Upon exercising the option and entering into a licensing agreement, KYORIN will provide Cyrano with an upfront payment, milestone payments tied to the progress of developing and commercializing CYR-064, and royalties based on a specified percentage of net sales following its launch. CYR-064, an novel, patent-protected, intranasal formulation of a broad-spectrum phosphodiesterase (PDE) inhibitor theophylline, is currently being administered in a Phase 2 clinical trial in the United States, with data from the trial expected in the second half of 2025. CYR-064 targets the inhibition of cAMP degradation thereby increasing intracellular concentrations and increasing olfactory neuron excitability, leading to a potential therapeutic effect in the treatment of post-viral hyposmia and potentially other olfactory disorders. Post-viral hyposmia is defined as a persistent olfactory dysfunction after an upper respiratory tract infection, even after the upper respiratory inflammation has subsided. A virus is the most common cause of olfactory dysfunction, followed by chronic rhinosinusitis, Parkinson's disease and head trauma. With the loss of smell, patients also lose up to 80% of their perception of taste. Forty% of patients with olfactory dysfunction also experience more than two safety events and 43% experience depression, significantly reducing a patient's quality of life. At present, there are no medications with clear evidence of effectiveness in treating post-viral hyposmic.

KYORIN Pharmaceutical Co., Ltd. provided dividend guidance for the fiscal year ending March 31, 2025. For the period, the company expects to pay JPY 32.00 per share as compared to JPY 32.00 per share paid a year ago.

KYORIN Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025

KYORIN Pharmaceutical Co., Ltd., 2025 Earnings Call, May 13, 2025

KYORIN Pharmaceutical Co., Ltd. expected to report Fiscal Year 2025 results on May 9, 2025. This event was calculated by S&P Global (Created on January 28, 2025).

KYORIN Pharmaceutical Co., Ltd. Presents at BIO Partnering @JPM Week, Jan-13-2025 . Venue: San Francisco Marriott Marquis, San Francisco, California, United States.

KYORIN Pharmaceutical Co., Ltd., ¥ 32.0, Cash Dividend, Mar-28-2025